Steinhardt H J, Loeschke K, Kasper H, Holtermüller K H, Schäfer H
Digestion. 1985;31(2-3):97-108. doi: 10.1159/000199186.
In the European Cooperative Crohn's Disease Study patients from 14 centers were included in whom diagnosis was made within 2 years before study entry on the basis of generally accepted radiological, endoscopical and/or histological criteria or a combination of all. Reasons for exclusion were: diagnosis older than 2 years in patients who did not require active treatment, age less than 18 years, duration of symptoms less than 3 months, presence of complications which potentially required emergency surgery. Data on clinical features were obtained in 633 patients, of whom 452 were eligible to participate in the study. In 110 patients randomized to placebo the natural course of Crohn's disease was studied. Patients with ileocolonic involvement were younger than patients with either colonic or small intestinal involvement only. Classic ileitis terminalis was present in 14% of the patients. 49% of the patients had combined involvement of both the small and large intestine. 30% of patients had only small intestinal involvement, and in 21% colonic disease was present. Small intestinal involvement was associated with a significantly lower Crohn's Disease Activity Index (CDAI) than other anatomical locations of the disease. Perianal disease was more often associated with colonic than with small intestinal involvement. 60% of placebo patients with active disease at entry achieved at least a transient remission within the initial 5 months of study. After 2 years, 23% of patients with active disease at entry and 68% of patients with quiescent disease had reached or maintained a remission, respectively. By stepwise multiple linear regression analysis long duration of disease between diagnosis and randomization, normal serum albumin and combined involvement of small intestine and colon were identified as predictors of a more favorable outcome of patients treated with placebo. In contrast, extensive small bowel disease, treatment with steroids and bowel resection prior to study entry correlated with a less favorable outcome. However, by life table analysis outcome of previously untreated and treated patients in the placebo group was similar.
在欧洲合作性克罗恩病研究中,纳入了来自14个中心的患者,这些患者在研究入组前2年内根据普遍认可的放射学、内镜学和/或组织学标准或所有这些标准的组合做出诊断。排除理由包括:对于不需要积极治疗的患者,诊断时间超过2年;年龄小于18岁;症状持续时间小于3个月;存在可能需要急诊手术的并发症。633例患者获得了临床特征数据,其中452例符合参与研究的条件。在随机分配到安慰剂组的110例患者中,研究了克罗恩病的自然病程。回结肠受累的患者比仅结肠或小肠受累的患者年轻。14%的患者存在典型的末端回肠炎。49%的患者同时累及小肠和大肠。30%的患者仅小肠受累,21%的患者存在结肠疾病。与疾病的其他解剖部位相比,小肠受累与显著更低的克罗恩病活动指数(CDAI)相关。肛周疾病更多与结肠受累相关,而非小肠受累。入组时患有活动性疾病的安慰剂组患者中,60%在研究的最初5个月内至少实现了短暂缓解。2年后,入组时患有活动性疾病的患者中有23%、静止期疾病患者中有68%分别达到或维持了缓解。通过逐步多元线性回归分析,诊断与随机分组之间疾病持续时间长、血清白蛋白正常以及小肠和结肠联合受累被确定为接受安慰剂治疗患者预后较好的预测因素。相比之下,广泛的小肠疾病、研究入组前使用类固醇治疗和肠道切除与较差的预后相关。然而,通过生命表分析,安慰剂组中既往未治疗和已治疗患者的预后相似。